<DOC>
	<DOC>NCT03058744</DOC>
	<brief_summary>Suppression Potential of Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects with Moderate to Severe Plaque Psoriasis.</brief_summary>
	<brief_title>Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis</brief_title>
	<detailed_description>A Phase 1b Open-Label, Randomized Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects with Moderate to Severe Plaque Psoriasis.</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Tazarotene</mesh_term>
	<mesh_term>Halobetasol</mesh_term>
	<mesh_term>Clobetasol</mesh_term>
	<criteria>Male or Female of any race, at least 18 years old of age (inclusive) Freely provides both written and oral informed consent. Has a clinical diagnosis of psoriasis at the Baseline visit with an Investigator's Global Assessment Score of 3 or 4. The face, scalp ,axillae, and intertriginous areas are to be excluded in this calculation. Has an area of plaque psoriasis for topical treatment that involves a BSA of at least 20%. The willing and able to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural and artificial) for the duration of the study. Key Has spontaneously improving or rapidly deteriorating plaque psoriasis or postural psoriasis, as determined by the investigator. Presents with psoriasis that was treated with prescription medication and failed to respond to presents). Has a history of adrenal disease. Presents with any other concurrent skin conditions that could interfere with the evaluation of the treatment areas, as determined by the investigator. Is pregnant, nursing, or planning pregnancy during the study period.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>